Theralink Technologies Inc   (OBMP)
Other Ticker:  
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00

 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 21,147
 Employees -
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -48
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Theralink Technologies Inc
Theralink Technologies, Inc., previously known as OncBioMune Pharmaceuticals, Inc., was a clinical-stage biopharmaceutical company that focused on developing novel cancer immunotherapy products and had a proprietary vaccine technology. On June 5, 2020, Theralink Technologies, Inc. acquired the assets of Avant Diagnostics, Inc., a commercial-stage precision medicine and molecular data-generating company that focuses on the development and commercialization of patented proprietary data-generating assays, through the Asset Sale Transaction. The company purchased substantially all of the assets of Avant, and assumed some of its liabilities. In consideration for the Asset Sale Transaction, Theralink Technologies, Inc. issued to Avant 1,000 shares of a newly created Series D-1 Preferred Stock, which held 54.55% of all voting rights on an as-converted basis with the common stock. Upon the effectiveness of an increase of the Company's authorized shares of common stock from 6,666,667 shares to 12,000,000,000 shares, all such shares of Series D-1 Preferred Stock issued to Avant automatically converted into 5,081,549,184 shares of the Company's common stock. Avant possessed majority voting control of the Company immediately following the Asset Sale Transaction, and controlled the Company's Board of Directors after the termination of the ten-day waiting period required by Rule 14f-1 under the Exchange Act. Therefore, the Asset Sale Transaction was accounted for as an asset acquisition of the Company's net assets by Avant and a recapitalization of Avant. On June 5, 2020, Theralink Technologies, Inc. entered into an employment agreement with Dr. Michael Ruxin to serve as the company's Chief Executive Officer, President and a director, entered into an employment agreement with Jeffery Busch to serve as the company's Chairman of the Board of Directors, and appointed Yvonne Fors to its Board of Directors, pursuant to the Asset Purchase Agreement. On August 14, 2020, the Board appointed Mr. Andrew Kucharchuk as Acting Chief Financial Officer of the Company, and approved a change in the Company's fiscal year-end from December 31 to September 30, effective immediately for the current fiscal year, and for all subsequent years until such time as the Board resolves to amend such fiscal year-end. The fiscal year has been changed to conform to the September 30 fiscal year-end of Avant, which is the historical registrant as a result of the Asset Sale Transaction consummated on June 5, 2020, and therefore, no transition report is required. On September 24, 2020, Andrew Kucharchuk resigned from his position as Acting Chief Financial Officer. Mr. Kucharchuk continues to serve as a director on the Company's Board of Directors. On the same day, the Company appointed Thomas E. Chilcott, III, to serve as the Chief Financial Officer. On April 1, 2022, the Board of Directors was expanded to six members, and Danica Holley and Matthew Schwartz were appointed to these newly created positions. Theralink Technologies, Inc. is a commercial-stage, precision medicine, molecular data-generating company that focuses on the development and commercialization of a series of proprietary data-generating assays that may provide important actionable information for physicians, patients and biopharmaceutical companies, in the area of oncology. The Company aims to commercialize the technology originally developed by Theranostics Health, Inc. The technology is differentiated due to the exclusive license agreement with George Mason University ('GMU'), the patent portfolio licensed from GMU and the National Institute of Health ('NIH'), access to GMU's well-p. In addition to its current product offerings, Theralink is also actively pursuing the development of new products, with a focus on expanding its precision oncology offerings. The company is working to develop assays that can be used to identify specific molecular targets that are associated with various types of cancer, with the goal of enabling more targeted and effective treatments for patients. Theralink has also established partnerships with other companies in the biopharmaceutical industry, in order to leverage its proprietary technology to support drug development and clinical trials. Through these partnerships, Theralink aims to generate additional revenue streams and expand the reach of its technology into new areas of oncology research and treatment. Overall, Theralink Technologies is a cutting-edge biopharmaceutical company with a focus on precision medicine and molecular data-generating assays for the diagnosis and treatment of cancer. With a strong patent portfolio and a team of experienced industry professionals, the company is well-positioned for continued growth and success in the years to come.

   Company Address: 15000 W. 6th Avenue Golden 80401 CO
   Company Phone Number: 420-0074   Stock Exchange / Ticker: OBMP
   OBMP is expected to report next financial results on December 28, 2023.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Evofem Biosciences Inc

Serious revenue fall, at Evofem Biosciences Inc in the fiscal third quarter of 2023

For the third quarter of 2023 Evofem Biosciences Inc had turn a round to earnings by posting EPS of $0.10 per share compare to $-0.04 a year prior and net profit per share turned positive from $-5.43 per share from the preceding financial reporting period. The revenue declined widely by -19.761 % to $5.11 million from $6.37 million in the corresponding financial reporting period a year prior and sequentially Revenue doubled by 107.974 % from $2.46 million.

Shuttle Pharmaceuticals Holdings Inc

Shuttle Pharmaceuticals Holdings Inc. Faces a Bumpy Ride: Operating Results Decline in Recent Fiscal Period for Major Pharmaceutical Preparations Company

In the dynamic and ever-evolving world of the stock market, there are always exciting new opportunities waiting to be discovered. While the major players in the pharmaceutical industry tend to grab most of the headlines, it is often the lesser-known companies that can offer hidden gems for astute investors. One such company, Shuttle Pharmaceuticals Holdings Inc (SHPH), has recently published its financial report for the third quarter of 2023, shedding light on its performance and potential for growth.
Despite reporting an operating loss of $-1.599146 million for the third quarter of 2023, SHPH has displayed a promising upward trajectory. Although the company has not released its top-line figures yet, it is essential to consider its previous accomplishments to put its recent performance into context. In the third quarter of 2022, SHPH recorded an operating loss of $-0.821468 million, indicating significant progress within just one year.

Cingulate Inc

The company declared operating shortfall in the third quarter of 2023

Bearish Sentiment Surrounding Cingulate Inc: A Closer Look at the Financials
Cingulate Inc, a Kansas City-based biopharmaceutical company operating in the Major Pharmaceutical Preparations sector, recently reported an operating shortfall of $-5.749674 million for the third quarter of 2023. This is a significant decrease when compared to the operating shortfall of $-3.968362 million reported in the same quarter of the previous year.
This decline in financial performance is a cause for concern. While companies in the pharmaceutical industry often experience fluctuations in revenue and profitability due to the challenges of developing innovative drugs, Cingulate Inc's consistent downward trend in operating shortfall is worrisome.
The management of Cingulate Inc aims to develop lucrative revenue sources by utilizing their proprietary Precision Timed Release (PTR) drug delivery platform technology. However, the results for the third quarter of 2023 indicate that these efforts have not yet yielded positive outcomes. The operating shortfall soared to $-5.979 million, indicating that the company's attempts to generate revenue have not been successful.

Harrow Inc

Harrow Inc Achieves Remarkable 49.84% Top-line Surge during Exceptional Q3 2023 Earnings Season

As the Chief Financial Correspondent at The , I would like to delve into the financial results of Harrow Inc for the fiscal period ending September 30, 2023. These results tell a story of progress and resilience in a volatile market. Despite recent decline in share values, Harrow Inc's steady financial improvement and increased revenue demonstrate its ability to navigate challenging times.
Profitability and Earnings:
Harrow Inc has made substantial progress in terms of earnings per share (EPS). In the fiscal year ending September 30, 2023, the company reduced its loss per share from $-0.24 to $-0.13. This represents a significant improvement in profitability, reflecting the company's strong management and strategic decisions.

Renovorx Inc

Renovorx Inc Witnesses Decline in Q3 2023 Financial Performance, Sets Path for Recovery

As the earnings season progresses, financial results of various companies are being unveiled. One notable player in the Major Pharmaceutical Preparations sector, Renovorx Inc, recently disclosed its operating loss for the most recent fiscal period ending September 30, 2023. While the figures may seem concerning at first glance, a closer look reveals some interesting developments that could shape the company's future trajectory.
Operating Loss Reduction:
Renovorx Inc reported an operating loss of $-2.983 million for the third quarter of 2023. However, comparing this figure with the same period in 2022, we see a positive trend. In the third quarter of 2022, the operating loss was $-2.161 million, indicating a reduction in losses year-over-year. This demonstrates the company's efforts to streamline operations and improve efficiency, which is essential for its long-term viability.


Theralink Technologies Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com